メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
伊藤 佳織
第１・薬剤部
h-index
167
被引用数
7
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2010
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(22)
類似のプロファイル
(6)
フィンガープリント
Kaori Itoが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
100%
Combination Therapy
90%
Cohort Study
81%
Ramucirumab
79%
Adverse Event
77%
Immune Checkpoint Inhibitor
76%
Colorectal Cancer
76%
Polypharmacy
71%
Non Small Cell Lung Cancer
54%
Chemotherapy
53%
Dexamethasone
44%
Adverse Drug Reaction
43%
Infection
43%
Retrospective Study
42%
Prescription Drug
42%
Ifosfamide
38%
Diffuse Large B Cell Lymphoma
38%
Herpes Zoster
38%
Erlotinib
38%
Carboplatin
38%
Neutropenia
38%
Meglumine
38%
Aprepitant
38%
Multiple Myeloma
38%
Cancer Chemotherapy
38%
Fosaprepitant
38%
Cytomegalovirus
38%
Liver Dysfunction
38%
Bevacizumab
38%
Nonhodgkin Lymphoma
38%
Bendamustine
38%
Vertebral Canal Stenosis
38%
Etoposide
38%
Docetaxel
38%
Blood Toxicity
38%
Allergic Reaction
38%
Bilirubin
38%
CD20 Antibody
38%
Benzodiazepine
38%
Musculoskeletal Disease
38%
Proteinuria
38%
Cytomegalovirus Infection
23%
Monotherapy
21%
Malignant Neoplasm
20%
Anticarcinogen
19%
Obinutuzumab
19%
Disease
19%
Prevalence
18%
First-Line Chemotherapy
17%
Epileptic Absence
13%
Keyphrases
Immune Checkpoint Inhibitors
54%
Ramucirumab
41%
Antibody-mediated Immunity
38%
IgG Levels
38%
Fosaprepitant
38%
Aprepitant
38%
Neutropenia
38%
Combination Therapy
38%
Docetaxel
38%
Pharmaceutical Consultation
38%
Cancer-associated Thrombosis
38%
L-OHP
38%
Immune Checkpoint Inhibitor Therapy
38%
Drug Survey
38%
Hematopoietic Function
38%
Serum IgG Level
38%
Relapsed Lymphoma
38%
CBDCA
38%
R-CHOP Therapy
38%
Combination of Therapies
38%
System Restoration
38%
Early Palliative Care
38%
MFOLFOX6
27%
Palliative Care Interventions
21%
Calvert Formula
21%
Post-chemotherapy
19%
TCR-T Therapy
19%
Thrombocytopaenia
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Delayed Vomiting
12%
Cancer of Unknown Primary
12%
Method Parameters
12%
Lymphocyte Count
12%
Ribosomal Protein Genes
12%
R-CHOP-14
12%
Absolute Reticulocyte Count
12%
R-CHOP-21
12%
CD20+
12%
Multiple Myeloma Patients
10%
Pleural Thymoma
10%
Incidence Rate
10%
Treatment History
10%
Self-management
9%
Anti-cancer Drug Treatment
9%
Bendamustine-rituximab
9%
National Comprehensive Cancer Network International Prognostic Index
7%
Infection Symptoms
7%
Population Groups
7%
Latent Factor Analysis
7%
High-dose Chemotherapy
6%
Medicine and Dentistry
Prescription Drug
42%
Spinal Stenosis
38%
Overall Survival
38%
Surgery
38%
Retrospective Study
38%
Symptomatic Treatment
38%
Pemetrexed
38%
Elderly Patient
38%
Immune Checkpoint Inhibitor
38%
Polypharmacy
38%
Blood Toxicity
38%
Disseminated Herpes Zoster
38%
Rituximab
38%
Spine Surgery
15%
Prevalence
14%
Cancer of Unknown Primary Origin
12%
Immunoglobulin
12%
Analgesia
7%
Pain Measurement
7%
Backache
7%
Orthopedics
7%
Complement Dependent Cytotoxicity
6%
CD20
6%
Infection Control
6%
Virus Reactivation
6%
Immune Deficiency
6%
Monoclonal Antibody
6%
Anticarcinogen
6%
Combined Therapy
6%
Antibody Dependent Cellular Cytotoxicity
6%
B-Cell Lymphoma
6%
Venous Thromboembolism
5%
Nivolumab
5%
Arterial Thromboembolism
5%
Treatment of Non-Small Cell Lung Cancer
5%
Knee Arthroplasty
5%
